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Introduction
Both the anti-ZIKV polyclonal rabbit and mouse sera containing high-titer immunoglobulin 143 recognizing all potential antigenic epitopes were generated at the Centers for Disease Control and 144 Prevention, Fort Collins, U.S.A. (US-CDC). Anti-DENV-2, DENV-3, or WNV VLP, and anti-NS1 145 polyclonal rabbit sera were produced in-house as described previously. Murine hyperimmune ascetic 146 fluid (MHIAF) specific for DENV-2 or DENV-3, or WNV were obtained from the Diagnostic and 147 Reference Laboratory, DVBD-CDC. Human serum specimens were assayed for the presence of prM/E-and NS1-specific antibodies 151 using MAC-ELISAs as previously described. 14, 20, 22, 23 Briefly, 96-well plates were coated with goat 152 anti-human IgM or IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD) diluted 1:2,000 in PBS at 153 pH 9.0 and incubated at 4°C overnight. The infected patient serum as well as negative control serum 154 were diluted 1:1,000 in wash buffer (PBS with 0.05% Tween-20), 50 µl were added to wells, and 155 incubated at 37°C for 60 min. ZIKV, DENV, WNV VLPs and NS1, pre-determined and standardized at 156 an optical density of 1·0 at 450nm (OD 450 ).by antigen-capture ELISA (Ag-ELISA), were diluted in wash 157 buffer and tested against each serum sample in triplicate. 158 To deplete anti-prM/E antibodies from serum samples, Ag-ELISA was used to capture VLP 159 immune-complexes in 96-well plates as previously suggested. 22, 23 In brief, the patient and negative 160 control sera were diluted 1:1,000 in PBS, mixed with VLP antigens, and added immediately to wells 161 pre-coated with anti-prM/E rabbit sera and incubated at 37°C for 60 min. A total of 50 L of prM/E 162 antibody-depleted sera were transferred to 96-well plates pre-coated with anti-human IgM for 163 performing the NS1-specific MAC-ELISA as described above. Data processing and statistical analysis 166 Both positive and negative values were determined as the average OD 450 from triplicate samples of 167 each specimen (P) or normal human control sera (N) reacting with VLP or NS1 antigens, respectively.
168
Positive-to-negative (P/N) ratios were derived for each specimen as well as positive and negative serum 169 controls on each plate for validation of the quality of the assay. The P/N ratios from the ZIKV patient 170 sera were compared with the ratios from different serum specimens from the test panel and the positive 171 likelihood ratio (LR+), shown as ROC curve, was calculated by dividing sensitivity by 1-specificity to 172 determine the optimal cutoff value of P/N ratios from VLP-and NS1-MAC-ELISAs.
173
The Bland-Altman plot was used to measure the consistency of higher P/N values of the ZIKV-over 174 DENV2-FP-MAC-ELISA, or ZIKV-over DENV2-NS1-MAC-ELISA by plotting the ratios of the two 175 methods' P/N ratio values (ratio of P/N value between ZIKV-MAC-ELISA and DENV2-MAC-ELISA) 176 versus the averages of P/N values from both methods. Two-by-two contingency tables were prepared to 177 determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value 178 (NPV) of the assays based on the algorithm generated in this study according to the validation serum 179 panel. For all statistical analyses, we used GraphPad Prism version 6 and p values less than 0·05 were 180 considered statistically significant. Figure 3B , 227 showing the curve of sensitivity vs 100-specificity, provides information on how strongly a given test 228 result can be used to predict the likelihood of evidence of infection or non-infection based on P/N values 229 from forty-two ZIKV patient sera and the WNV/other control serum panels ( Fig 3B) . The optimal cutoff 230 values of P/N ratios for both ZIKV-VLP-MAC-ELISAs of acute and convalescent phase sera were set at 231 2.837 and 2.76, respectively (Fig. 3C) . Similarly, the results of ZIKV-NS1-MAC-ELISAs for four 232 different serum panels are shown in Fig 4A. The optimal cutoff values of P/N ratios for ZIKV-NS1-233 MAC-ELISAs of both acute and convalescent sera were set at 1.014 and 1.136, respectively ( Fig. 4B 234 and 4C).
235
Based on the cutoff, similar percentages of ZIKV acute (69.6% and 69.6%), and convalescent 236 sera (94.7% and 100%) were positive for both ZIKV-VLP and NS1-MAC-ELISA, respectively (Table   237 2). However, significant numbers of the DENV panel were also positive to ZIKV VLP (63.6%) and 238 NS1-MAC-ELISAs (72.7%). When ZIKV serum specimens were tested against DENV2 VLP and NS1 239 antigens, 95.7% were positive to VLP but only 8.7% were positive to NS1 from acute phase sera. On the 240 contrary, 100% and 52.6% of the convalescent phase sera were positive for VLP and NS1 antigens of 241 DENV-2, respectively. In summary, our VLP-and NS1-MAC-ELISAs have similar sensitivity detecting 242 anti-prM/E and NS1 antibodies from ZIKV-infected patient sera. Although a significantly lower 243 percentage of ZIKV patient sera was positive to NS1 antigens than VLP of DENV-2, no difference of 244 cross-reactivity to ZIKV antigens was observed for DENV patient sera.
246
Using ZIKV/DENV2 ratio to differentiate between ZIKV and DENV infection 247 Previous studies suggested that a significant proportion of anti-E antibodies were GR antibodies 248 that recognized the highly conserved fusion peptide during flavivirus infection. 24, 28 To avoid the binding 249 of such GR antibodies on the ZIKV VLP, a fusion peptide mutant ZIKV VLP (ZIKV FP-VLP) was 250 generated for MAC-ELISA and the proper cutoff value was determined ( Fig S1) . A significant decrease 251 of the cross-reactivity to ZIKV FP-VLP among the DENV serum panel was noticed; in addition, a 252 similar positive proportion among the ZIKV serum panel was detected (Table S1 ). Therefore, our data 253 suggested that FP-VLP, compared to WT-VLP as a diagnostic reagent, would be a more specific antigen 254 for detecting anti-prM/E antibodies although there were still nearly 40% of DENV sera cross-reactive 255 with ZIKV FP-VLP.
256
Further comparing the P/N ratios of the MAC-ELISA between ZIKV and DENV-2 FP-VLP, 257 consistently higher values were observed when using homologous antigens; that is, for a ZIKV infection, 258 higher values of the P/N ratio was observed for ZIKV FP-VLP than for the use of DENV-2 FP-VLP ( Fig   259   5 ). Similar results were also observed for the NS1-MAC-ELISA. Therefore, an algorithm of serological 260 diagnosis to differentiate between ZIKV and DENV infection was developed in this study (Fig 6) . (Table S2) (Table S3 ). The majority of ZIKV-infected patients had prior DENV infection as 296 suggested by FRµNT titers greater than 10 against DENV-2 in acute serum specimens. During 297 secondary ZIKV infection, the FRµNT titer in the convalescent sera showed at least 4-fold increase indicate that cross-neutralization with polyclonal sera is usually lost when the amino acid sequence 310 divergence of E is more than 50%. 7 Therefore, ZIKV together with the viruses from the Spondweni 311 virus group could form an independent serocomplex, which serves as the basis of using the ratio of 312 ZIKV/DENV IgM antibodies for a differential diagnosis. A similar concept could also be applied to 313 anti-NS1 antibodies, which share a similar amino acid sequence divergence with viruses from different 314 serocomplexes. The use of FP-VLP in this study has several advantages, including the avoidance of a 315 pre-depletion step prior to detecting anti-NS1 antibodies, and the reduced binding of cross-reactive Our study revealed a similar percentage of ZIKV acute (69 . 6% and 69.6%), and convalescent 319 sera (94 . 7% and 100%) were positive for both ZIKV-VLP and NS1-MAC-ELISA, respectively.
320
Previous publications suggested a lower sensitivity of detecting anti-NS1 antibodies, possibly due to 321 their relatively low abundance compared to anti-prM/E antibody in human sera. 15, 22 Our study showed 322 that depletion of anti-prM/E antibodies enhances the sensitivity of NS1 antibody detection. Based on the 323 testing algorithm developed in this study, FP-VLP-MAC-ELISA and NS1-MAC-ELISA had similar 324 PPV and NPV (Table 2 ). By combining both assays, the accuracy of sero-diagnosis can reach up to 95% 325 (57/60) using the classification guideline provided in Table S4 . Considering the severe outcome of 326 congenital Zika syndrome, three false positive specimens (5%), misclassified as ZIKV infections, may 327 be acceptable (Table S5 ). The important limitations of the current study is the small sample size of the 328 validation serum panel and the generalizability to a more complex serum panels such as subjects with 329 prior exposure to St. Louis Encephalitis virus, Japanese encephalitis virus, Powassan virus, and yellow 330 fever virus. In summary, the current study successfully develops a novel approach to accurately 331 differentiate ZIKV and DENV infections for evidence-based public health intervention.
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